Research on Adenocarcinoma Reported by Researchers at Affiliated Hospital of Jiaxing University (SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling).

Researchers at the Affiliated Hospital of Jiaxing University in China have conducted a study on gemcitabine resistance in pancreatic ductal adenocarcinoma. They found that the expression of Solute carrier 39A1 (SLC39A1) was significantly up-regulated in gemcitabine-resistant samples compared to gemcitabine-sensitive ones. The study also revealed that SLC39A1 promotes gemcitabine resistance by activating AMP-activated protein kinase (AMPK) signaling. These findings suggest that SLC39A1 may be a potential target for overcoming gemcitabine resistance in pancreatic ductal adenocarcinoma patients. [Extracted from the article]